SCHEMBL22834243

SCHEMBL22834243

CC(C)(Cc1ccccc1)NC(=O)Nc1ccc(Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 8/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56
ALDH1A1 P00352 2/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
TSHR P16473 1/20 0.51
MEN1 O00255 1/20 0.49
LMNA P02545 1/20 0.49
MAPT P10636 1/20 0.49
KMT2A Q03164 1/20 0.49
OPRM1 P35372 1/20 0.48
OPRD1 P41143 1/20 0.48
OPRK1 P41145 1/20 0.48
POLB P06746 1/20 0.48
PPARG P37231 1/20 0.48
PPARA Q07869 1/20 0.48
CASR P41180 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10931520 0.79 KMT2A (0.61) CNR1SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL3135163 0.77 CYP3A4 (0.51) NPC1RAB9AALDH1A1CYP3A4CYP2C9
SCHEMBL15946354 0.76 NPC1 (0.68) CNR1SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL13182410 0.76 CNR1 (0.61) CNR1SMN1; SMN2TSHR
SCHEMBL1492691 0.76 WNT3A (0.64)
SCHEMBL11461831 0.75 SMN1; SMN2 (0.68) CNR1SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL5948337 0.74 CYP3A4 (0.67) SMN1; SMN2NPC1RAB9AALDH1A1CYP3A4
SCHEMBL23069098 0.74 ALDH1A1 (0.68) CNR1SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL8177097 0.74 RAB9A (0.72) CNR1SMN1; SMN2NPC1RAB9AMEN1
SCHEMBL11054644 0.74 CNR1 (0.74) CNR1SMN1; SMN2NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220332695-A1 UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS RESEARCH TRIANGLE INSTITUTE 2022-10-20 US claimed
EP-3990112-A1 UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS RTI International (US) 2022-05-04 EP claimed
CN-114269719-A Urea derivatives as CB1 allosteric modulators RTI国际 2022-04-01 CN claimed
WO-2020264176-A1 UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS RTI INTERNATIONAL (US) 2020-12-30 WO claimed
US-20220332695-A1 UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS RESEARCH TRIANGLE INSTITUTE 2022-10-20 US disclosed
EP-3990112-A1 UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS RTI International (US) 2022-05-04 EP disclosed
CN-114269719-A Urea derivatives as CB1 allosteric modulators RTI国际 2022-04-01 CN disclosed
WO-2020264176-A1 UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS RTI INTERNATIONAL (US) 2020-12-30 WO disclosed
WO-2020264176-A1 UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS RTI INTERNATIONAL (US) 2020-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332695-A1 UREA DERIVATIVES AS CB1 ALLOSTERIC MODULATORS CNR1, CNR2, GPR119 CNR1 1/4885SMN1; SMN2 4012/4885NPC1 571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.